Auxogyn has announced the European Union launch of its non-invasive early embryo viability assessment (Eeva) test, designed to improve in-vitro fertilisation outcomes.

By using intelligent computer vision software, Eeva measures clinically validated cell-division parameters from video images and provides clinicians and patients with objective information to more confidently select embryos for transfer.

Eeva also predicts, with high accuracy at the cleavage stage, which embryos are likely to grow to the blastocyst stage, a critical stage in embryo development, according to the company.

The company has installed Eeva test at the Hewitt Fertility Centre in Liverpool, UK.

Hewitt Fertility Centre lead consultant and Liverpool Women’s National Health Service Hospital Foundation Trust consultant gynaecologist Charles Kingsland said the centre is adopting new technologies to improve embryo selection in order to increase pregnancy success while reducing the risks associated with multiple births.

"By using Eeva, we will be able to help our patients make more informed personal decisions and provide them with the best care possible," Kingsland said.

The safety and efficacy of Eeva was validated in a prospective, multi-centre, 160-patient clinical trial, which demonstrated that the test was able to predict blastocyst formation at the cleavage stage with 85% specificity, reducing the false-positive rate from 43% to 15%, compared with traditional morphology selection.

Eeva also demonstrated the ability to track and analyse cell division timings with greater than 90% accuracy and was able to increase the consistency of embryo assessment across embryologists.

The company said Eeva is not yet cleared in the US and is limited to investigational use only.